Safety and tolerability of abciximab in patients with acute miocardial infarction and failed thrombolysis

International Journal of Cardiology

Volumn 92, Issue 2-3, 2003, Pages 265-270

  Di Pasquale, Pietro ^a   Cannizzaro, Sergio ^a   Scalzo, Sebastiano ^a   Maringhini, Giorgio ^a   Vitrano, Gabriella M ^a   Giubilato, Alfonso ^a   Giambanco, Francesco ^b   Sarullo, Filippo M ^c   Paterna, Salvatore ^d  

^a Ospedale GF Ingrassia   (Italy)

^b Civic Hospital   (Italy)

^c Buccheri La Ferla Hospital   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Acute myocardial infarction; Failed thrombolysis; GP IIb IIIa inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; METOPROLOL; NITRATE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBRINOLYTIC THERAPY; HEART RUPTURE; HEMATEMESIS; HEMATURIA; HEMOPERICARDIUM; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION; RESTENOSIS; RETROPERITONEAL HEMORRHAGE; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION; STENT; SYMPTOM; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0345097381     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(03)00085-8     Document Type: Article

References (27)

1. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
2. Mauri F., Gasparrini M., Barbonagia I., et al. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated with streptokinase (the GISSI trial). Am J Cardiol. 63:1989;1291-1295.
3. Stone G.W., Grines C.L., Browne K.F., et al. Predictor of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the primary angioplasty in myocardial infarction (PAMI trial). J Am Col Cardiol. 25:1995;370-377.
4. Outcome of attempted rescue coronary angioplasty after failed thrombolysis for acute myocardial infarction. Am J Cardiol. 74:1994;172-174.
5. The effects of tissue plasminogen activator, streptokinase, or both, on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615-1622.
6. Ohman EM, Califf RM, Topol EJ, for the TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-91.
7. Sarullo F.M., Americo L., Di Pasquale P., Castello A., Mauri F. Efficacy of rescue thrombolysis in patients with acute myocardial infarction: preliminary findings. Cardiovasc Drugs Ther. 14:1999;83-89.
8. Antman EM, Giugliano RP, Gibson CM et al. for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Abciximab facilitates the rate and the extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 99 (1999) 2720-32.
9. Core J.M., Sloan M., Price T., et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study: Thrombolysis in myocardial infarction, phase II, pilot and clinical trial. Circulation. 83:1991;448-459.
10. Topol E.J. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation. 97:1998;211-218.
11. Fuster V., Lewis A. Conner Memorial lecture: mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 90:1994;2126-2146.
12. Badimon L., Badimon J.J., Taritto V.T., Vallabhjosula S., Fuster V. Platelet thrombus formation on collagen type I: a model of deep vessel injury: influence of blood rheo, von Willebrand factor, and blood coagulation. Circulation. 78:1988;1431-1442.
13. Merlini P.A., Bauer K.A., Oltrona L., et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 25:1995;203-208.
14. Gulba D.C., Barthels M., Westhoff-Bleck M., et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation. 83:1991;937-944.
15. Coller B.S. Platelets and thrombolytic therapy. N Engl J Med. 322:1990;33-42.
16. Coller B.S. GP IIb/IIIa antagonists: pathophysiology and therapeutic insights from studies of c7E3 fab. Thromb Haemost. 78:1997;730-755.
17. Van Belle E., Lablanche J.-M., Bauters C., Renaud N., McFadden E.P., Bertrand M.E. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation. 97:1998;26-33.
18. Coller B.S., Peerschke El., Scudder L.E., Sullivan C.A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelet and produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 72:1983;325-338.
19. Ohman EM, Kleiman NS, Gacioch G et al. for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: results of a randomized, placebo controlled, dose ranging trial. Circulation 1997;95:846-54.
20. Ohman E.M., Lincoff M., Bole C., et al. Enhanced early reperfusion at 60 min with low dose reteplase combined with full dose abciximab in acute myocardial infarction:preliminary results from the GUSTO-4 pilot (SPEED) dose ranging trial (abstract). Circulation. 98:(Suppl. I):1998;504.
21. de Lemos J.A., Antman E.M., Gibson C.M., et al. Abciximab improve both epicardial flow and myocardial reperfusion in ST elevation myocardial infarction: a TIMl 14 analysis. Circulation. 101:2000;239-243.
22. Core J.M., Sloan M., Price T., et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction study: Thrombolysis in Myocardial Infarction, phase II, pilot and clinical trial. Circulation. 83:1991;448-459.
23. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357 (2001) 1905-14.
24. Deckers J., Califf R.M., Topol W.F., et al. Use of abciximab (ReoPro) is not associated with an increase in the risk of stroke: overview of three randomized trials (abstr.). J Am Coll Cardiol. 29:(Suppl. A):1997;241A.
25. Cantor W.J., Kaplan A.L., Velianou J.L., et al. Effectiveness and safety of abciximab after failed thrombolytic therapy. Am J Cardiol. 87:2001;439-442.
26. La Vecchia L., Martini M., Bottero M., et al. Abciximab in rescue coronary angioplasty after full-dose tissue-type plasminogen activator. Ital Heart J. 2:(4):2001;301-305.
27. Cannon P.C. Overcoming thrombolytic resistance. J Am Coll Cardiol. 34:1999;1395-1402.